These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 15684117)

  • 1. Economic evaluation of sirolimus-eluting stents.
    Shrive FM; Manns BJ; Galbraith PD; Knudtson ML; Ghali WA;
    CMAJ; 2005 Feb; 172(3):345-51. PubMed ID: 15684117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: results from the Sirolimus-Eluting Balloon Expandable Stent in the Treatment of Patients With De Novo Native Coronary Artery Lesions (SIRIUS) trial.
    Cohen DJ; Bakhai A; Shi C; Githiora L; Lavelle T; Berezin RH; Leon MB; Moses JW; Carrozza JP; Zidar JP; Kuntz RE;
    Circulation; 2004 Aug; 110(5):508-14. PubMed ID: 15262844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization: results from the TAXUS-IV Trial.
    Bakhai A; Stone GW; Mahoney E; Lavelle TA; Shi C; Berezin RH; Lahue BJ; Clark MA; Lacey MJ; Russell ME; Ellis SG; Hermiller JB; Cox DA; Cohen DJ;
    J Am Coll Cardiol; 2006 Jul; 48(2):253-61. PubMed ID: 16843171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The dollars and sense of drug-eluting stents.
    Brophy JM
    CMAJ; 2005 Feb; 172(3):361-2. PubMed ID: 15684119
    [No Abstract]   [Full Text] [Related]  

  • 5. Cost analysis from two randomized trials of sirolimus-eluting stents versus paclitaxel-eluting stents in high-risk patients with coronary artery disease.
    Elezi S; Dibra A; Folkerts U; Mehilli J; Heigl S; Schömig A; Kastrati A
    J Am Coll Cardiol; 2006 Jul; 48(2):262-7. PubMed ID: 16843172
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of everolimus- versus paclitaxel-eluting stents for patients undergoing percutaneous coronary revascularization (from the SPIRIT-IV Trial).
    Amin AP; Reynolds MR; Lei Y; Magnuson EA; Vilain K; Durtschi AJ; Simonton CA; Stone GW; Cohen DJ
    Am J Cardiol; 2012 Sep; 110(6):765-70. PubMed ID: 22651880
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of the unrestricted use of sirolimus-eluting stents vs. bare metal stents at 1 and 2-year follow-up: results from the RESEARCH Registry.
    Ong AT; Daemen J; van Hout BA; Lemos PA; Bosch JL; van Domburg RT; Serruys PW
    Eur Heart J; 2006 Dec; 27(24):2996-3003. PubMed ID: 17114234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic impact of drug-eluting stents on hospital systems: a disease-state model.
    Kong DF; Eisenstein EL; Sketch MH; Zidar JP; Ryan TJ; Harrington RA; Newman MF; Smith PK; Mark DB; Califf RM
    Am Heart J; 2004 Mar; 147(3):449-56. PubMed ID: 14999193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of drug-eluting stents in patients at high or low risk of major cardiac events in the Basel Stent KostenEffektivitäts Trial (BASKET): an 18-month analysis.
    Brunner-La Rocca HP; Kaiser C; Bernheim A; Zellweger MJ; Jeger R; Buser PT; Osswald S; Pfisterer M;
    Lancet; 2007 Nov; 370(9598):1552-9. PubMed ID: 17980734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost effectiveness of the sirolimus-eluting stent in high-risk patients in Canada: an analysis from the C-SIRIUS trial.
    Rinfret S; Cohen DJ; Tahami Monfared AA; Lelorier J; Mireault J; Schampaert E
    Am J Cardiovasc Drugs; 2006; 6(3):159-68. PubMed ID: 16780389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-eluting or sirolimus-eluting stents to prevent restenosis in diabetic patients.
    Dibra A; Kastrati A; Mehilli J; Pache J; Schühlen H; von Beckerath N; Ulm K; Wessely R; Dirschinger J; Schömig A;
    N Engl J Med; 2005 Aug; 353(7):663-70. PubMed ID: 16105990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Moving beyond the cost per quality-adjusted life year: modelling the budgetary impact and clinical outcomes associated with the use of sirolimus-eluting stents.
    Shrive FM; Ghali WA; Lewis S; Donaldson C; Knudtson ML; Manns BJ
    Can J Cardiol; 2005 Jul; 21(9):783-7. PubMed ID: 16082437
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of sirolimus-eluting stents in percutaneous coronary interventions in Brazil.
    Polanczyk CA; Wainstein MV; Ribeiro JP
    Arq Bras Cardiol; 2007 Apr; 88(4):464-74. PubMed ID: 17546279
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
    Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
    N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The paclitaxel-eluting stent in percutaneous coronary intervention: Part II. Comparison with the sirolimus-eluting stent, economics, and unanswered questions.
    Ray GM; Nawarskas JJ; Frishman WH
    Cardiol Rev; 2006; 14(3):143-50. PubMed ID: 16628023
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of cost-saving and effectiveness of oral rapamycin plus bare-metal stents with drug-eluting stents: three-year outcome from the randomized oral rapamycin in Argentina (ORAR) III trial.
    Rodriguez AE; Rodriguez-Granillo AM; Antoniucci D; Mieres J; Fernandez-Pereira C; Rodriguez-Granillo GA; Santaera O; Rubilar B; Palacios IF; Serruys PW;
    Catheter Cardiovasc Interv; 2012 Sep; 80(3):385-94. PubMed ID: 22109997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents.
    Spaulding C; Daemen J; Boersma E; Cutlip DE; Serruys PW
    N Engl J Med; 2007 Mar; 356(10):989-97. PubMed ID: 17296825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review and economic analysis of drug-eluting coronary stents available in Australia.
    Lord SJ; Howard K; Allen F; Marinovich L; Burgess DC; King R; Atherton JJ
    Med J Aust; 2005 Nov; 183(9):464-71. PubMed ID: 16274347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Safety and current indications during "real life" use of sirolimus-eluting coronary stents in Germany. Results from the prospective multicenter German Cypher Registry].
    Zahn R; Hamm CW; Zeymer U; Schneider S; Nienaber CA; Richardt G; Kelm M; Levenson B; Bonzel T; Tebbe U; Schöbel WA; Sabin G; Senges J;
    Herz; 2004 Mar; 29(2):181-6. PubMed ID: 15057439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes and cost-utility after sirolimus-eluting versus bare metal stent implantation.
    Zhao FH; Lü SZ; Li H; Ning SQ; Yuan F; Song XT; Jin ZN; Zhou Y; Chen X; Liu H; Tian R; Meng K; Li H; Han F
    Chin Med J (Engl); 2010 Oct; 123(20):2797-802. PubMed ID: 21034585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.